Biotech & Genomic Medicine▲
Assembly Biosciences Reports Q2 2026 Results and Pipeline Updates
Assembly Biosciences reported second quarter 2026 financial results and announced expansion of ABI-6250 into cholestatic liver diseases including primary biliary cholangitis and primary sclerosing cholangitis. The company completed a $115 million gross financing and projects cash runway into 2029, including the first $75 million Gilead collaboration extension payment due in the fourth quarter of 2026. Gilead selected GS-1179, formerly ABI-1179, to advance in the HSV helicase primase inhibitor program with Phase 2 initiation expected by year-end 2026. Net loss attributable to common stockholders was $3.9 million, or $0.20 per share, compared to $10.2 million, or $1.33 per share, in the same period last year. Cash, cash equivalents and marketable securities totaled $320.4 million as of June 30, 2026.